Skip to main content
. Author manuscript; available in PMC: 2011 Oct 1.
Published in final edited form as: Antiviral Res. 2010 Jul 13;88(1):38–44. doi: 10.1016/j.antiviral.2010.07.003

Table 2.

Combinations of oseltamivir carboxylate and peramivir against influenza A/NWS/33 (H1N1) neuraminidase.

Oseltamivir
Carboxylate
(nM)
Peramivir (nM)
0 0.01 0.032 0.1 0.32 1.0 3.2 10
10 7 ± 0.3a 6 ± 0.5 6 ± 0.4 6 ± 0.9 5 ± 1.1 4 ± 0.4 2 ± 0.4 1 ± 0.2
3.2 18 ± 1.1 16 ± 1.3 15 ± 0.4 15 ± 1.3 12 ± 1.3 6 ± 0.2 2 ± 0.4 1 ± 0.1
1.0 39 ± 3.5 34 ± 2.8 33 ± 2.4 26 ± 2.7 15 ± 1.6 6 ± 0.6 2 ± 0.3 1 ± 0.2
0.32 65 ± 6.9 58 ± 6.5 55 ± 0.8 43 ± 4.4 18 ± 1.3 5 ± 0.5 2 ± 0.3 1 ± 0.2
0.1 88 ± 6.7 84 ± 4.6 72 ± 4.0 50 ± 3.6 18 ± 1.2 5 ± 0.5 2 ± 0.3 1 ± 0.2
0.032 99 ± 3.7 93 ± 9.1 78 ± 2.8 52 ± 7.1 23 ± 4.2 4 ± 1.0 2 ± 0.3 1 ± 0.3
0.01 103 ± 3.0 95 ± 4.1 79 ± 7.8 55 ± 6.8 18 ± 2.2 4 ± 0.2 2 ± 0.2 1 ± 0.9
0 100 ± 0.0 102 ± 5.1 87 ± 8.3 58 ± 6.6 21 ± 2.1 5 ± 0.4 2 ± 0.1 1 ± 0.2
a

Values are percentages of untreated control ± SD for three independent assays.